ZA200407182B - Dexanabinol and dexanabinol analogs regulate inflammation releated genes. - Google Patents

Info

Publication number

ZA200407182B

ZA200407182B ZA200407182A ZA200407182A ZA200407182B ZA 200407182 B ZA200407182 B ZA 200407182B ZA 200407182 A ZA200407182 A ZA 200407182A ZA 200407182 A ZA200407182 A ZA 200407182A ZA 200407182 B ZA200407182 B ZA 200407182B

Authority

ZA

South Africa

Prior art keywords

saturated

cyclic

unsaturated

branched

inflammatory

Prior art date

2002-03-18

Links

• Espacenet
• Global Dossier
• Discuss

• 230000004054 inflammatory process Effects 0.000 title claims description 27
• 206010061218 Inflammation Diseases 0.000 title claims description 18
• 108090000623 proteins and genes Proteins 0.000 title description 73
• SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 title description 65
• 150000001875 compounds Chemical class 0.000 claims description 117
• 102000004127 Cytokines Human genes 0.000 claims description 84
• 108090000695 Cytokines Proteins 0.000 claims description 84
• 125000004122 cyclic group Chemical group 0.000 claims description 80
• 108010002350 Interleukin-2 Proteins 0.000 claims description 72
• 229920006395 saturated elastomer Polymers 0.000 claims description 72
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 65
• 102000000588 Interleukin-2 Human genes 0.000 claims description 64
• 125000000217 alkyl group Chemical group 0.000 claims description 54
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 52
• 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 41
• 230000003110 anti-inflammatory effect Effects 0.000 claims description 41
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 39
• 102100040247 Tumor necrosis factor Human genes 0.000 claims description 36
• 239000000203 mixture Substances 0.000 claims description 36
• 201000010099 disease Diseases 0.000 claims description 35
• 230000002757 inflammatory effect Effects 0.000 claims description 33
• 208000035475 disorder Diseases 0.000 claims description 30
• -1 1,1-dimethylheptyl Chemical group 0.000 claims description 28
• 230000000770 proinflammatory effect Effects 0.000 claims description 27
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 24
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 24
• 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims description 23
• 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 claims description 23
• 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 claims description 23
• 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 claims description 23
• 239000004480 active ingredient Substances 0.000 claims description 22
• 125000005842 heteroatom Chemical group 0.000 claims description 22
• 230000001105 regulatory effect Effects 0.000 claims description 21
• 102000000589 Interleukin-1 Human genes 0.000 claims description 19
• 108010002352 Interleukin-1 Proteins 0.000 claims description 19
• 229910052799 carbon Inorganic materials 0.000 claims description 19
• 125000004414 alkyl thio group Chemical group 0.000 claims description 18
• 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims description 17
• 102100039065 Interleukin-1 beta Human genes 0.000 claims description 17
• 230000001965 increasing effect Effects 0.000 claims description 17
• 239000008194 pharmaceutical composition Substances 0.000 claims description 17
• 125000003545 alkoxy group Chemical group 0.000 claims description 16
• 125000000623 heterocyclic group Chemical group 0.000 claims description 16
• 238000013518 transcription Methods 0.000 claims description 16
• 230000035897 transcription Effects 0.000 claims description 16
• 208000002193 Pain Diseases 0.000 claims description 15
• 239000003814 drug Substances 0.000 claims description 15
• 210000000056 organ Anatomy 0.000 claims description 15
• 230000036407 pain Effects 0.000 claims description 15
• 125000001424 substituent group Chemical group 0.000 claims description 15
• 230000011664 signaling Effects 0.000 claims description 14
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 13
• 229930194542 Keto Natural products 0.000 claims description 13
• 125000003118 aryl group Chemical group 0.000 claims description 13
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
• 125000000468 ketone group Chemical group 0.000 claims description 13
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
• 230000001681 protective effect Effects 0.000 claims description 13
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
• 238000004519 manufacturing process Methods 0.000 claims description 12
• 230000001404 mediated effect Effects 0.000 claims description 11
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 11
• 150000003839 salts Chemical class 0.000 claims description 11
• 125000004429 atom Chemical group 0.000 claims description 10
• 229910052739 hydrogen Inorganic materials 0.000 claims description 10
• 239000001257 hydrogen Substances 0.000 claims description 10
• 210000001616 monocyte Anatomy 0.000 claims description 10
• 201000006417 multiple sclerosis Diseases 0.000 claims description 10
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
• 208000024827 Alzheimer disease Diseases 0.000 claims description 9
• 208000018737 Parkinson disease Diseases 0.000 claims description 9
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
• 208000019423 liver disease Diseases 0.000 claims description 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
• 150000001412 amines Chemical class 0.000 claims description 8
• 125000004432 carbon atom Chemical group C* 0.000 claims description 8
• 150000002148 esters Chemical class 0.000 claims description 8
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
• 229910052736 halogen Inorganic materials 0.000 claims description 7
• 150000002367 halogens Chemical class 0.000 claims description 7
• 230000004614 tumor growth Effects 0.000 claims description 7
• 201000001320 Atherosclerosis Diseases 0.000 claims description 6
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
• 208000006673 asthma Diseases 0.000 claims description 6
• 239000003085 diluting agent Substances 0.000 claims description 6
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
• QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical compound C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 claims description 5
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 5
• 206010040047 Sepsis Diseases 0.000 claims description 5
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 5
• 206010052779 Transplant rejections Diseases 0.000 claims description 5
• 239000000839 emulsion Substances 0.000 claims description 5
• 230000008595 infiltration Effects 0.000 claims description 5
• 238000001764 infiltration Methods 0.000 claims description 5
• 208000017169 kidney disease Diseases 0.000 claims description 5
• 238000002360 preparation method Methods 0.000 claims description 5
• 239000012453 solvate Substances 0.000 claims description 5
• 150000003457 sulfones Chemical class 0.000 claims description 5
• 150000003462 sulfoxides Chemical class 0.000 claims description 5
• 150000007970 thio esters Chemical group 0.000 claims description 5
• UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical group CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 claims description 4
• 208000035143 Bacterial infection Diseases 0.000 claims description 4
• 206010027476 Metastases Diseases 0.000 claims description 4
• 208000012902 Nervous system disease Diseases 0.000 claims description 4
• 208000025966 Neurological disease Diseases 0.000 claims description 4
• 206010033645 Pancreatitis Diseases 0.000 claims description 4
• 208000030852 Parasitic disease Diseases 0.000 claims description 4
• 208000035965 Postoperative Complications Diseases 0.000 claims description 4
• 206010047115 Vasculitis Diseases 0.000 claims description 4
• 150000001408 amides Chemical group 0.000 claims description 4
• 230000001580 bacterial effect Effects 0.000 claims description 4
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
• 150000001721 carbon Chemical group 0.000 claims description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
• 239000007943 implant Substances 0.000 claims description 4
• 208000027866 inflammatory disease Diseases 0.000 claims description 4
• 230000009401 metastasis Effects 0.000 claims description 4
• 230000003071 parasitic effect Effects 0.000 claims description 4
• 201000000306 sarcoidosis Diseases 0.000 claims description 4
• 125000001391 thioamide group Chemical group 0.000 claims description 4
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
• 208000036142 Viral infection Diseases 0.000 claims description 3
• 230000002159 abnormal effect Effects 0.000 claims description 3
• 230000009285 allergic inflammation Effects 0.000 claims description 3
• 230000003247 decreasing effect Effects 0.000 claims description 3
• 208000033699 familial Guillain-Barre syndrome Diseases 0.000 claims description 3
• 208000026278 immune system disease Diseases 0.000 claims description 3
• 238000001356 surgical procedure Methods 0.000 claims description 3
• 150000003573 thiols Chemical class 0.000 claims description 3
• 201000008827 tuberculosis Diseases 0.000 claims description 3
• 230000009385 viral infection Effects 0.000 claims description 3
• OXFSTTJBVAAALW-UHFFFAOYSA-N 1,3-dihydroimidazole-2-thione Chemical group SC1=NC=CN1 OXFSTTJBVAAALW-UHFFFAOYSA-N 0.000 claims description 2
• 239000002736 nonionic surfactant Substances 0.000 claims description 2
• 239000004094 surface-active agent Substances 0.000 claims description 2
• 150000003626 triacylglycerols Chemical class 0.000 claims description 2
• 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 5
• 102000004889 Interleukin-6 Human genes 0.000 claims 5
• 108090001005 Interleukin-6 Proteins 0.000 claims 5
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 5
• 102000003814 Interleukin-10 Human genes 0.000 claims 4
• 108090000174 Interleukin-10 Proteins 0.000 claims 4
• 208000019693 Lung disease Diseases 0.000 claims 4
• 201000004624 Dermatitis Diseases 0.000 claims 2
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
• 239000006184 cosolvent Substances 0.000 claims 2
• 208000033679 diabetic kidney disease Diseases 0.000 claims 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
• 241000112708 Vates Species 0.000 claims 1
• 238000013130 cardiovascular surgery Methods 0.000 claims 1
• 239000002563 ionic surfactant Substances 0.000 claims 1
• 239000000787 lecithin Substances 0.000 claims 1
• 229940067606 lecithin Drugs 0.000 claims 1
• 235000010445 lecithin Nutrition 0.000 claims 1
• 230000014509 gene expression Effects 0.000 description 125
• 241001465754 Metazoa Species 0.000 description 117
• 210000004027 cell Anatomy 0.000 description 102
• 238000012360 testing method Methods 0.000 description 76
• 230000000694 effects Effects 0.000 description 71
• 238000011282 treatment Methods 0.000 description 69
• 108010062580 Concanavalin A Proteins 0.000 description 52
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 50
• 239000007924 injection Substances 0.000 description 48
• 238000002347 injection Methods 0.000 description 48
• 239000003981 vehicle Substances 0.000 description 45
• 241000699670 Mus sp. Species 0.000 description 42
• 235000002639 sodium chloride Nutrition 0.000 description 39
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
• 102000000018 Chemokine CCL2 Human genes 0.000 description 36
• 210000004185 liver Anatomy 0.000 description 34
• 210000004556 brain Anatomy 0.000 description 33
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
• 238000000034 method Methods 0.000 description 31
• 230000028327 secretion Effects 0.000 description 30
• 239000011780 sodium chloride Substances 0.000 description 30
• 230000006378 damage Effects 0.000 description 28
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 24
• 230000004913 activation Effects 0.000 description 24
• 239000002158 endotoxin Substances 0.000 description 24
• 229920006008 lipopolysaccharide Polymers 0.000 description 23
• 102000004169 proteins and genes Human genes 0.000 description 23
• 210000001744 T-lymphocyte Anatomy 0.000 description 22
• 208000027418 Wounds and injury Diseases 0.000 description 22
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
• 208000014674 injury Diseases 0.000 description 22
• 210000002540 macrophage Anatomy 0.000 description 22
• 235000018102 proteins Nutrition 0.000 description 22
• 210000001519 tissue Anatomy 0.000 description 21
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 20
• 206010067125 Liver injury Diseases 0.000 description 20
• 231100000753 hepatic injury Toxicity 0.000 description 20
• 230000006698 induction Effects 0.000 description 20
• 230000005764 inhibitory process Effects 0.000 description 20
• 230000009467 reduction Effects 0.000 description 20
• 210000002683 foot Anatomy 0.000 description 19
• 230000002441 reversible effect Effects 0.000 description 19
• 210000000952 spleen Anatomy 0.000 description 18
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
• 230000001225 therapeutic effect Effects 0.000 description 17
• 235000013350 formula milk Nutrition 0.000 description 16
• PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 15
• 206010028980 Neoplasm Diseases 0.000 description 15
• 230000033228 biological regulation Effects 0.000 description 15
• 230000002829 reductive effect Effects 0.000 description 15
• 101150071146 COX2 gene Proteins 0.000 description 14
• 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 14
• 238000000540 analysis of variance Methods 0.000 description 14
• 238000001727 in vivo Methods 0.000 description 13
• 238000007912 intraperitoneal administration Methods 0.000 description 13
• 230000007423 decrease Effects 0.000 description 12
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 11
• 108010082126 Alanine transaminase Proteins 0.000 description 11
• 102000019034 Chemokines Human genes 0.000 description 11
• 108010012236 Chemokines Proteins 0.000 description 11
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 11
• 230000009286 beneficial effect Effects 0.000 description 11
• 238000002474 experimental method Methods 0.000 description 11
• 230000000506 psychotropic effect Effects 0.000 description 11
• 238000003753 real-time PCR Methods 0.000 description 11
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• 210000004369 blood Anatomy 0.000 description 10
• 239000008280 blood Substances 0.000 description 10
• 230000037396 body weight Effects 0.000 description 10
• 229930003827 cannabinoid Natural products 0.000 description 10
• 239000003557 cannabinoid Substances 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 210000003734 kidney Anatomy 0.000 description 10
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 10
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 10
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
• 102000011767 Acute-Phase Proteins Human genes 0.000 description 9
• 108010062271 Acute-Phase Proteins Proteins 0.000 description 9
• 208000023275 Autoimmune disease Diseases 0.000 description 9
• 229930105110 Cyclosporin A Natural products 0.000 description 9
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 9
• 108010036949 Cyclosporine Proteins 0.000 description 9
• 239000003795 chemical substances by application Substances 0.000 description 9
• 230000001684 chronic effect Effects 0.000 description 9
• 229960001265 ciclosporin Drugs 0.000 description 9
• 229960004279 formaldehyde Drugs 0.000 description 9
• 238000000338 in vitro Methods 0.000 description 9
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 9
• 239000013641 positive control Substances 0.000 description 9
• 150000003180 prostaglandins Chemical class 0.000 description 9
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
• 108060001084 Luciferase Proteins 0.000 description 8
• 239000005089 Luciferase Substances 0.000 description 8
• 230000006044 T cell activation Effects 0.000 description 8
• 230000001154 acute effect Effects 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 239000003710 calcium ionophore Substances 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 8
• 239000008103 glucose Substances 0.000 description 8
• 230000000302 ischemic effect Effects 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 102000008186 Collagen Human genes 0.000 description 7
• 108010035532 Collagen Proteins 0.000 description 7
• 230000009471 action Effects 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 230000001363 autoimmune Effects 0.000 description 7
• 210000003169 central nervous system Anatomy 0.000 description 7
• 229920001436 collagen Polymers 0.000 description 7
• 201000002491 encephalomyelitis Diseases 0.000 description 7
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 7
• 230000001603 reducing effect Effects 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 210000003491 skin Anatomy 0.000 description 7
• 239000003356 suture material Substances 0.000 description 7
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 7
• LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 6
• 238000002965 ELISA Methods 0.000 description 6
• 108010051696 Growth Hormone Proteins 0.000 description 6
• 102000014702 Haptoglobin Human genes 0.000 description 6
• 108050005077 Haptoglobin Proteins 0.000 description 6
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 6
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 6
• 201000004681 Psoriasis Diseases 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• 102100038803 Somatotropin Human genes 0.000 description 6
• 208000006011 Stroke Diseases 0.000 description 6
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 6
• 230000000903 blocking effect Effects 0.000 description 6
• 229960003957 dexamethasone Drugs 0.000 description 6
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
• 239000000122 growth hormone Substances 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 108020004999 messenger RNA Proteins 0.000 description 6
• 230000004770 neurodegeneration Effects 0.000 description 6
• 229960001412 pentobarbital Drugs 0.000 description 6
• 230000019491 signal transduction Effects 0.000 description 6
• 238000007619 statistical method Methods 0.000 description 6
• 230000005951 type IV hypersensitivity Effects 0.000 description 6
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 5
• 108020004635 Complementary DNA Proteins 0.000 description 5
• 229930182816 L-glutamine Natural products 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 5
• 239000013614 RNA sample Substances 0.000 description 5
• 229930006000 Sucrose Natural products 0.000 description 5
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
• 108091023040 Transcription factor Proteins 0.000 description 5
• 102000040945 Transcription factor Human genes 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 229940114079 arachidonic acid Drugs 0.000 description 5
• 235000021342 arachidonic acid Nutrition 0.000 description 5
• 210000001367 artery Anatomy 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 238000010804 cDNA synthesis Methods 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 210000000269 carotid artery external Anatomy 0.000 description 5
• 210000004004 carotid artery internal Anatomy 0.000 description 5
• 210000001072 colon Anatomy 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• 230000002596 correlated effect Effects 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 206010012601 diabetes mellitus Diseases 0.000 description 5
• 230000002222 downregulating effect Effects 0.000 description 5
• 229960004242 dronabinol Drugs 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 235000019256 formaldehyde Nutrition 0.000 description 5
• 231100000283 hepatitis Toxicity 0.000 description 5
• 230000002443 hepatoprotective effect Effects 0.000 description 5
• 210000000548 hind-foot Anatomy 0.000 description 5
• 210000003630 histaminocyte Anatomy 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 230000028709 inflammatory response Effects 0.000 description 5
• 230000000977 initiatory effect Effects 0.000 description 5
• 230000000926 neurological effect Effects 0.000 description 5
• 229910052760 oxygen Inorganic materials 0.000 description 5
• 230000001575 pathological effect Effects 0.000 description 5
• 230000007170 pathology Effects 0.000 description 5
• 239000008389 polyethoxylated castor oil Substances 0.000 description 5
• 230000035755 proliferation Effects 0.000 description 5
• 229940054269 sodium pyruvate Drugs 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 239000005720 sucrose Substances 0.000 description 5
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 4
• 201000006474 Brain Ischemia Diseases 0.000 description 4
• 102000003952 Caspase 3 Human genes 0.000 description 4
• 108090000397 Caspase 3 Proteins 0.000 description 4
• 206010009944 Colon cancer Diseases 0.000 description 4
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
• 208000011231 Crohn disease Diseases 0.000 description 4
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
• 208000009386 Experimental Arthritis Diseases 0.000 description 4
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
• 102000015617 Janus Kinases Human genes 0.000 description 4
• 108010024121 Janus Kinases Proteins 0.000 description 4
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
• 206010030113 Oedema Diseases 0.000 description 4
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
• 108010075383 Suppressor of Cytokine Signaling Proteins Proteins 0.000 description 4
• 102000008036 Suppressor of Cytokine Signaling Proteins Human genes 0.000 description 4
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 4
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
• 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 4
• 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 4
• 210000001642 activated microglia Anatomy 0.000 description 4
• 238000002399 angioplasty Methods 0.000 description 4
• 230000006907 apoptotic process Effects 0.000 description 4
• 206010003246 arthritis Diseases 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 208000029028 brain injury Diseases 0.000 description 4
• 229940065144 cannabinoids Drugs 0.000 description 4
• 239000000679 carrageenan Substances 0.000 description 4
• 235000010418 carrageenan Nutrition 0.000 description 4
• 229920001525 carrageenan Polymers 0.000 description 4
• 229940113118 carrageenan Drugs 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 230000002708 enhancing effect Effects 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 239000012894 fetal calf serum Substances 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 208000006454 hepatitis Diseases 0.000 description 4
• 125000002636 imidazolinyl group Chemical group 0.000 description 4
• 125000002883 imidazolyl group Chemical group 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 230000002093 peripheral effect Effects 0.000 description 4
• 210000001428 peripheral nervous system Anatomy 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 230000035790 physiological processes and functions Effects 0.000 description 4
• 125000004193 piperazinyl group Chemical group 0.000 description 4
• 125000005936 piperidyl group Chemical group 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
• 125000000168 pyrrolyl group Chemical group 0.000 description 4
• 230000011514 reflex Effects 0.000 description 4
• 210000004988 splenocyte Anatomy 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 4
• 125000003831 tetrazolyl group Chemical group 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 125000001425 triazolyl group Chemical group 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
• KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• 208000007788 Acute Liver Failure Diseases 0.000 description 3
• 206010000804 Acute hepatic failure Diseases 0.000 description 3
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 244000025254 Cannabis sativa Species 0.000 description 3
• 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 3
• 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 3
• 206010008120 Cerebral ischaemia Diseases 0.000 description 3
• 206010009900 Colitis ulcerative Diseases 0.000 description 3
• 208000035473 Communicable disease Diseases 0.000 description 3
• 108010072220 Cyclophilin A Proteins 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• 206010012289 Dementia Diseases 0.000 description 3
• 206010012442 Dermatitis contact Diseases 0.000 description 3
• 206010016654 Fibrosis Diseases 0.000 description 3
• 208000015872 Gaucher disease Diseases 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 102000047918 Myelin Basic Human genes 0.000 description 3
• 101710107068 Myelin basic protein Proteins 0.000 description 3
• 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 3
• 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 3
• 239000004677 Nylon Substances 0.000 description 3
• 241000721454 Pemphigus Species 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 238000002123 RNA extraction Methods 0.000 description 3
• 206010040070 Septic Shock Diseases 0.000 description 3
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 3
• 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 3
• CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 description 3
• 206010046851 Uveitis Diseases 0.000 description 3
• 206010052428 Wound Diseases 0.000 description 3
• 210000001015 abdomen Anatomy 0.000 description 3
• 238000002835 absorbance Methods 0.000 description 3
• 208000038016 acute inflammation Diseases 0.000 description 3
• 230000006022 acute inflammation Effects 0.000 description 3
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
• 230000000202 analgesic effect Effects 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 238000003491 array Methods 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 210000001168 carotid artery common Anatomy 0.000 description 3
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 3
• 229960000590 celecoxib Drugs 0.000 description 3
• 230000020411 cell activation Effects 0.000 description 3
• 239000013592 cell lysate Substances 0.000 description 3
• 206010008118 cerebral infarction Diseases 0.000 description 3
• 208000037976 chronic inflammation Diseases 0.000 description 3
• 230000006020 chronic inflammation Effects 0.000 description 3
• 230000007882 cirrhosis Effects 0.000 description 3
• 208000019425 cirrhosis of liver Diseases 0.000 description 3
• 208000010247 contact dermatitis Diseases 0.000 description 3
• 229940111134 coxibs Drugs 0.000 description 3
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 230000007123 defense Effects 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
• 230000003828 downregulation Effects 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 210000003494 hepatocyte Anatomy 0.000 description 3
• 210000001320 hippocampus Anatomy 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 210000000936 intestine Anatomy 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 239000012139 lysis buffer Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 201000008383 nephritis Diseases 0.000 description 3
• 210000000653 nervous system Anatomy 0.000 description 3
• 230000000324 neuroprotective effect Effects 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 238000010606 normalization Methods 0.000 description 3
• 229920001778 nylon Polymers 0.000 description 3
• 230000000771 oncological effect Effects 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 210000000496 pancreas Anatomy 0.000 description 3
• 230000007310 pathophysiology Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 230000004983 pleiotropic effect Effects 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 230000001144 postural effect Effects 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 125000003226 pyrazolyl group Chemical group 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 208000023504 respiratory system disease Diseases 0.000 description 3
• 230000000284 resting effect Effects 0.000 description 3
• 230000036303 septic shock Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 210000003523 substantia nigra Anatomy 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 229960001967 tacrolimus Drugs 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• 208000009935 visceral pain Diseases 0.000 description 3
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 3
• 229960001600 xylazine Drugs 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
• IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 2
• MTIMDGQILFWMJI-UHFFFAOYSA-N 2-methylsulfanyl-4,5-dihydro-1h-imidazole Chemical compound CSC1=NCCN1 MTIMDGQILFWMJI-UHFFFAOYSA-N 0.000 description 2
• OVABIFHEPZPSCK-UHFFFAOYSA-N 5,5-dimethyl-1,4-dihydroimidazole Chemical compound CC1(C)CN=CN1 OVABIFHEPZPSCK-UHFFFAOYSA-N 0.000 description 2
• WTWSDDKGKIGSJE-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 WTWSDDKGKIGSJE-UHFFFAOYSA-N 0.000 description 2
• STFIZEBRSSCPKA-UHFFFAOYSA-N 5-methyl-4,5-dihydro-1h-imidazole Chemical compound CC1CNC=N1 STFIZEBRSSCPKA-UHFFFAOYSA-N 0.000 description 2
• 206010048998 Acute phase reaction Diseases 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 206010001889 Alveolitis Diseases 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 206010071155 Autoimmune arthritis Diseases 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 108010074051 C-Reactive Protein Proteins 0.000 description 2
• 102100032752 C-reactive protein Human genes 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 241000700199 Cavia porcellus Species 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 108090001069 Chymopapain Proteins 0.000 description 2
• 229920000858 Cyclodextrin Polymers 0.000 description 2
• 108010068682 Cyclophilins Proteins 0.000 description 2
• 102000001493 Cyclophilins Human genes 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 206010012689 Diabetic retinopathy Diseases 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
• 108700039887 Essential Genes Proteins 0.000 description 2
• 208000007882 Gastritis Diseases 0.000 description 2
• 208000018522 Gastrointestinal disease Diseases 0.000 description 2
• 229930182566 Gentamicin Natural products 0.000 description 2
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 206010019196 Head injury Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
• 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 2
• 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
• 102100034343 Integrase Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 102000009112 Mannose-Binding Lectin Human genes 0.000 description 2
• 108010087870 Mannose-Binding Lectin Proteins 0.000 description 2
• 101000897464 Mus musculus C-C motif chemokine 2 Proteins 0.000 description 2
• 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 101001078375 Mus musculus Haptoglobin Proteins 0.000 description 2
• 101001033265 Mus musculus Interleukin-10 Proteins 0.000 description 2
• 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 2
• 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 2
• 101001124986 Mus musculus Nitric oxide synthase, inducible Proteins 0.000 description 2
• 101001067830 Mus musculus Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 2
• 101000605126 Mus musculus Prostaglandin G/H synthase 2 Proteins 0.000 description 2
• 101100041608 Mus musculus Saa3 gene Proteins 0.000 description 2
• 101000687809 Mus musculus Suppressor of cytokine signaling 1 Proteins 0.000 description 2
• 101000652217 Mus musculus Suppressor of cytokine signaling 3 Proteins 0.000 description 2
• 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 2
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
• WFKPHYKFAOXUTI-UHFFFAOYSA-N NP-101A Chemical compound CC(=O)NC1=CC=CC=C1C(N)=O WFKPHYKFAOXUTI-UHFFFAOYSA-N 0.000 description 2
• 206010029164 Nephrotic syndrome Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
• 206010033799 Paralysis Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 2
• 102100035194 Placenta growth factor Human genes 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
• 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 208000037062 Polyps Diseases 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 102000010635 Protein Inhibitors of Activated STAT Human genes 0.000 description 2
• 108010038241 Protein Inhibitors of Activated STAT Proteins 0.000 description 2
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
• 239000012979 RPMI medium Substances 0.000 description 2
• 206010063897 Renal ischaemia Diseases 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 229940124639 Selective inhibitor Drugs 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• 206010072170 Skin wound Diseases 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 238000000692 Student's t-test Methods 0.000 description 2
• 101001018322 Sus scrofa Myelin basic protein Proteins 0.000 description 2
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• GPKUGWDQUVWHIC-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NNC1=CC=C(C=C1)C1=CC=C(NN)C=C1 GPKUGWDQUVWHIC-UHFFFAOYSA-N 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 230000004658 acute-phase response Effects 0.000 description 2
• 125000004423 acyloxy group Chemical group 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940124599 anti-inflammatory drug Drugs 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 210000000436 anus Anatomy 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 210000001130 astrocyte Anatomy 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 230000002902 bimodal effect Effects 0.000 description 2
• 230000027455 binding Effects 0.000 description 2
• 230000036765 blood level Effects 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 235000001465 calcium Nutrition 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 229960005069 calcium Drugs 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 229940109239 creatinine Drugs 0.000 description 2
• 229940097362 cyclodextrins Drugs 0.000 description 2
• YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 230000002939 deleterious effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
• 238000002224 dissection Methods 0.000 description 2
• 229960003638 dopamine Drugs 0.000 description 2
• 210000005064 dopaminergic neuron Anatomy 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
• 230000001605 fetal effect Effects 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 238000007710 freezing Methods 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 229960002518 gentamicin Drugs 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 230000001434 glomerular Effects 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 230000009931 harmful effect Effects 0.000 description 2
• 231100000234 hepatic damage Toxicity 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 102000047486 human GAPDH Human genes 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
• NBGMRMDAEWWFIR-UHFFFAOYSA-N imidazole-2-thione Chemical compound S=C1N=CC=N1 NBGMRMDAEWWFIR-UHFFFAOYSA-N 0.000 description 2
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000002991 immunohistochemical analysis Methods 0.000 description 2
• 238000012744 immunostaining Methods 0.000 description 2
• 229940124589 immunosuppressive drug Drugs 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000010874 in vitro model Methods 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000004968 inflammatory condition Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000017306 interleukin-6 production Effects 0.000 description 2
• 229940028435 intralipid Drugs 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 230000003447 ipsilateral effect Effects 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 230000008818 liver damage Effects 0.000 description 2
• 238000004020 luminiscence type Methods 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 238000002493 microarray Methods 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• 210000001577 neostriatum Anatomy 0.000 description 2
• 208000009928 nephrosis Diseases 0.000 description 2
• 231100001027 nephrosis Toxicity 0.000 description 2
• WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
• 208000004296 neuralgia Diseases 0.000 description 2
• 230000002314 neuroinflammatory effect Effects 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 230000002981 neuropathic effect Effects 0.000 description 2
• 208000021722 neuropathic pain Diseases 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 229960000988 nystatin Drugs 0.000 description 2
• VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 102000013415 peroxidase activity proteins Human genes 0.000 description 2
• 108040007629 peroxidase activity proteins Proteins 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 238000010149 post-hoc-test Methods 0.000 description 2
• 238000004321 preservation Methods 0.000 description 2
• 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 2
• 208000005069 pulmonary fibrosis Diseases 0.000 description 2
• DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 238000004445 quantitative analysis Methods 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000037425 regulation of transcription Effects 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 230000010410 reperfusion Effects 0.000 description 2
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
• 238000010825 rotarod performance test Methods 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 208000020431 spinal cord injury Diseases 0.000 description 2
• 238000013222 sprague-dawley male rat Methods 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 230000008093 supporting effect Effects 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 238000012353 t test Methods 0.000 description 2
• BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
• 229930192474 thiophene Natural products 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 239000003656 tris buffered saline Substances 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 208000016261 weight loss Diseases 0.000 description 2
• 230000004580 weight loss Effects 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical class C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
• NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
• OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
• GUQHFZFTGHNVDG-UHFFFAOYSA-N 1h-1,2,4-triazole-5-carbonitrile Chemical compound N#CC1=NC=NN1 GUQHFZFTGHNVDG-UHFFFAOYSA-N 0.000 description 1
• XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
• QMGUOJYZJKLOLH-UHFFFAOYSA-N 3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1h-indol-3-yl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(CCCN(C)C)C=C1C1=C(C=2C3=CC=CC=C3NC=2)C(=O)NC1=O QMGUOJYZJKLOLH-UHFFFAOYSA-N 0.000 description 1
• 101150110188 30 gene Proteins 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010002388 Angina unstable Diseases 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• 241000195940 Bryophyta Species 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 description 1
• 241000218236 Cannabis Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102000004041 Caspase 7 Human genes 0.000 description 1
• 108090000567 Caspase 7 Proteins 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
• WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
• 244000089742 Citrus aurantifolia Species 0.000 description 1
• 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
• 241001573498 Compacta Species 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
• 208000005171 Dysmenorrhea Diseases 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• 206010017065 Foster-Kennedy Syndrome Diseases 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• 101000965150 Glycine max Isocitrate lyase 2 Proteins 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 241000589989 Helicobacter Species 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
• 206010019851 Hepatotoxicity Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
• 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 208000004454 Hyperalgesia Diseases 0.000 description 1
• 206010065390 Inflammatory pain Diseases 0.000 description 1
• 101150109636 Inos gene Proteins 0.000 description 1
• 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
• 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
• 102000003810 Interleukin-18 Human genes 0.000 description 1
• 108090000171 Interleukin-18 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 206010025327 Lymphopenia Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 238000000585 Mann–Whitney U test Methods 0.000 description 1
• 241000252067 Megalops atlanticus Species 0.000 description 1
• 206010027202 Meningitis bacterial Diseases 0.000 description 1
• 206010027260 Meningitis viral Diseases 0.000 description 1
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
• 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 208000026072 Motor neurone disease Diseases 0.000 description 1
• 208000034486 Multi-organ failure Diseases 0.000 description 1
• 208000010718 Multiple Organ Failure Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101100113998 Mus musculus Cnbd2 gene Proteins 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 206010065673 Nephritic syndrome Diseases 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• 101710138657 Neurotoxin Proteins 0.000 description 1
• 206010067482 No adverse event Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 206010033892 Paraplegia Diseases 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102000016611 Proteoglycans Human genes 0.000 description 1
• 108010067787 Proteoglycans Proteins 0.000 description 1
• 206010037714 Quadriplegia Diseases 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 241000084978 Rena Species 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 206010048988 Renal artery occlusion Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 108700028909 Serum Amyloid A Proteins 0.000 description 1
• 102000054727 Serum Amyloid A Human genes 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• 241000534944 Thia Species 0.000 description 1
• 235000011941 Tilia x europaea Nutrition 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 238000010162 Tukey test Methods 0.000 description 1
• 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• 238000007216 Upjohn dihydroxylation reaction Methods 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 206010047141 Vasodilatation Diseases 0.000 description 1
• 206010047249 Venous thrombosis Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 210000003489 abdominal muscle Anatomy 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 231100000836 acute liver failure Toxicity 0.000 description 1
• 239000002313 adhesive film Substances 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 208000002353 alcoholic hepatitis Diseases 0.000 description 1
• 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 208000002029 allergic contact dermatitis Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000001384 anti-glaucoma Effects 0.000 description 1
• 230000001754 anti-pyretic effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000002221 antipyretic Substances 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 230000009925 apoptotic mechanism Effects 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 230000002917 arthritic effect Effects 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 201000009904 bacterial meningitis Diseases 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 238000009227 behaviour therapy Methods 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 230000000035 biogenic effect Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 230000000981 bystander Effects 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 230000002149 cannabinoid effect Effects 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 229940000032 cardiovascular system drug Drugs 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 239000002975 chemoattractant Substances 0.000 description 1
• 230000002113 chemopreventative effect Effects 0.000 description 1
• 230000001767 chemoprotection Effects 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 239000000769 chromic catgut Substances 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• WTEVQBCEXWBHNA-JXMROGBWSA-N citral A Natural products CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 230000008094 contradictory effect Effects 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 108091008034 costimulatory receptors Proteins 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000003235 crystal violet staining Methods 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 230000010250 cytokine signaling pathway Effects 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 230000009274 differential gene expression Effects 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 230000009266 disease activity Effects 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 239000012154 double-distilled water Substances 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 150000002066 eicosanoids Chemical class 0.000 description 1
• 230000001712 encephalitogenic effect Effects 0.000 description 1
• 238000007824 enzymatic assay Methods 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
• 229960001123 epoprostenol Drugs 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 230000008713 feedback mechanism Effects 0.000 description 1
• 210000003191 femoral vein Anatomy 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000012054 flavored emulsion Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 239000008098 formaldehyde solution Substances 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000011990 functional testing Methods 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 230000007387 gliosis Effects 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 210000000224 granular leucocyte Anatomy 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 238000001631 haemodialysis Methods 0.000 description 1
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
• 229960003132 halothane Drugs 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 230000000322 hemodialysis Effects 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000334 hepatotoxic Toxicity 0.000 description 1
• 230000003082 hepatotoxic effect Effects 0.000 description 1
• 231100000304 hepatotoxicity Toxicity 0.000 description 1
• 230000007686 hepatotoxicity Effects 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000002134 immunopathologic effect Effects 0.000 description 1
• 239000003547 immunosorbent Substances 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000003960 inflammatory cascade Effects 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 239000002555 ionophore Substances 0.000 description 1
• 230000000236 ionophoric effect Effects 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
• 108010052968 leupeptin Proteins 0.000 description 1
• 238000011694 lewis rat Methods 0.000 description 1
• 239000004571 lime Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 230000005976 liver dysfunction Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000003137 locomotive effect Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 231100001023 lymphopenia Toxicity 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• 210000003584 mesangial cell Anatomy 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000021039 metastatic melanoma Diseases 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 210000003657 middle cerebral artery Anatomy 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000023185 monocyte chemotactic protein-1 production Effects 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 235000011929 mousse Nutrition 0.000 description 1
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 239000006225 natural substrate Substances 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000003589 nefrotoxic effect Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 230000001607 nephroprotective effect Effects 0.000 description 1
• 231100000381 nephrotoxic Toxicity 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 230000001067 neuroprotector Effects 0.000 description 1
• 239000002581 neurotoxin Substances 0.000 description 1
• 231100000618 neurotoxin Toxicity 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000012053 oil suspension Substances 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 230000020477 pH reduction Effects 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 238000005192 partition Methods 0.000 description 1
• 235000011837 pasties Nutrition 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 238000012335 pathological evaluation Methods 0.000 description 1
• 230000008529 pathological progression Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 108010091212 pepstatin Proteins 0.000 description 1
• FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 210000002824 peroxisome Anatomy 0.000 description 1
• 238000011458 pharmacological treatment Methods 0.000 description 1
• 230000010118 platelet activation Effects 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 208000015768 polyposis Diseases 0.000 description 1
• 229920000131 polyvinylidene Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000007943 positive regulation of appetite Effects 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 230000000272 proprioceptive effect Effects 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 230000004224 protection Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
• 150000003235 pyrrolidines Chemical class 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 208000000029 referred pain Diseases 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 210000002254 renal artery Anatomy 0.000 description 1
• 230000008085 renal dysfunction Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 210000003497 sciatic nerve Anatomy 0.000 description 1
• 238000013077 scoring method Methods 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 230000037351 starvation Effects 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 230000008409 synovial inflammation Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 150000003595 thromboxanes Chemical class 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000008791 toxic response Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 102000014898 transaminase activity proteins Human genes 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 210000002993 trophoblast Anatomy 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 229940087652 vioxx Drugs 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 201000010044 viral meningitis Diseases 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000005406 washing Methods 0.000 description 1